Home Cart 0 Sign in  
X

[ CAS No. 5927-18-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
3d Animation Molecule Structure of 5927-18-4
Chemical Structure| 5927-18-4
Chemical Structure| 5927-18-4
Structure of 5927-18-4 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 5927-18-4 ]

Related Doc. of [ 5927-18-4 ]

Alternatived Products of [ 5927-18-4 ]

Product Details of [ 5927-18-4 ]

CAS No. :5927-18-4 MDL No. :MFCD00008452
Formula : C5H11O5P Boiling Point : -
Linear Structure Formula :- InChI Key :SIGOIUCRXKUEIG-UHFFFAOYSA-N
M.W : 182.11 Pubchem ID :80029
Synonyms :

Calculated chemistry of [ 5927-18-4 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.8
Num. rotatable bonds : 5
Num. H-bond acceptors : 5.0
Num. H-bond donors : 0.0
Molar Refractivity : 38.27
TPSA : 71.64 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.84 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.63
Log Po/w (XLOGP3) : -0.61
Log Po/w (WLOGP) : 0.65
Log Po/w (MLOGP) : -0.55
Log Po/w (SILICOS-IT) : -0.57
Consensus Log Po/w : 0.11

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -0.25
Solubility : 101.0 mg/ml ; 0.556 mol/l
Class : Very soluble
Log S (Ali) : -0.42
Solubility : 68.8 mg/ml ; 0.378 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -0.63
Solubility : 42.3 mg/ml ; 0.232 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 3.37

Safety of [ 5927-18-4 ]

Signal Word:Danger Class:9
Precautionary Statements:P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P310-P330-P362+P364-P403+P233-P501 UN#:3082
Hazard Statements:H302-H315-H318-H335-H411 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 5927-18-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 5927-18-4 ]
  • Downstream synthetic route of [ 5927-18-4 ]

[ 5927-18-4 ] Synthesis Path-Upstream   1~19

  • 1
  • [ 50-00-0 ]
  • [ 5927-18-4 ]
  • [ 15484-46-5 ]
YieldReaction ConditionsOperation in experiment
44% With potassium carbonate In water at 20℃; for 2 h; Example 106: methyl 2-(hydroxymethyl)acrylate44percentA saturated aqueous solution (10 mL) of K2CO3 (3.5 g, 117 mmol, 1.6 eq.) was slowly added to a rapidly stirred solution of trimethylphosphonoacetate (5.46 g, 30 mmol, 1.0 eq.) and paraformaldehyde (6.63 g, 48 mmol, 4.0 eq.) at r.t.. After the addition the mixture was stirred for 2 h. Then the mixture was extracted with DCM. The organic layer was concentrated to give the compound (1.5 g, 44percent) as a yellow oil. 1U NMR (400 MHz, CD3OD) δ: 6.29 (s, IH), 5.83 (s, IH), 3.75 (s, 3H), 3.72 (s, 2H).
Reference: [1] Angewandte Chemie - International Edition, 2015, vol. 54, # 6, p. 1929 - 1932[2] Angew. Chem., 2015, vol. 127, # 6, p. 1949 - 1952,4
[3] Tetrahedron, 2008, vol. 64, # 17, p. 3701 - 3712
[4] Patent: WO2011/17561, 2011, A1, . Location in patent: Page/Page column 72
[5] Journal of Medicinal Chemistry, 1998, vol. 41, # 18, p. 3539 - 3545
  • 2
  • [ 50-00-0 ]
  • [ 5927-18-4 ]
  • [ 15484-46-5 ]
  • [ 292638-85-8 ]
YieldReaction ConditionsOperation in experiment
56% With potassium carbonate In water at 23℃; Acrylate 20. Synthesized by a method adapted from Villieras and Rambaud.2 To around-bottom flask equipped with a stir bar were added trimethyl phosphonoacetate (S1,9.1 mL, 63 mmol, 1.00 equiv) and formaldehyde (S2, 20.5g, 37percent in water, 252 mmol,4.00 equiv). The flask was lowered into a ambient-temperature water bath. To themixture was added a saturated solution of potassium carbonate in water (15.3 g, 110mmol, 1.75 equiv) dropwise via addition funnel over the course of one hour, and stirringwas continued for an additional hour. The reaction mixture was quenched by addition ofsaturated aqueous ammonium chloride (30 mL), then extracted three times with diethylether. The combined organics were washed with brine, dried over anhydrous magnesiumsulfate, filtered, and concentrated in vacuo. Methyl acrylate, produced as a side-product,was removed by azeotropic distillation with methanol. The residue was purified byvacuum distillation (~0.5 torr, 44 °C) to afford acrylate 20 as a clear oil (4.07 g, 56percentyield) with minor impurities which were carried forward to the next reaction. Thecharacterization data matched those reported in the literature.3
Reference: [1] Tetrahedron Letters, 2015, vol. 56, # 23, p. 2983 - 2990
  • 3
  • [ 111-71-7 ]
  • [ 5927-18-4 ]
  • [ 111-79-5 ]
Reference: [1] European Journal of Organic Chemistry, 2009, # 4, p. 554 - 563
  • 4
  • [ 67-56-1 ]
  • [ 16139-79-0 ]
  • [ 311-46-6 ]
  • [ 5927-18-4 ]
  • [ 625396-69-2 ]
  • [ 625396-71-6 ]
Reference: [1] Chemical and Pharmaceutical Bulletin, 2005, vol. 53, # 1, p. 131 - 134
  • 5
  • [ 96-34-4 ]
  • [ 868-85-9 ]
  • [ 5927-18-4 ]
Reference: [1] Russian Journal of General Chemistry, 2015, vol. 85, # 10, p. 2441 - 2448[2] Ross. Khim. Zh., 2014, vol. 58, # 1, p. 23 - 30,8
  • 6
  • [ 67-56-1 ]
  • [ 88738-78-7 ]
  • [ 5927-18-4 ]
  • [ 681123-85-3 ]
Reference: [1] Chemical and Pharmaceutical Bulletin, 2005, vol. 53, # 1, p. 131 - 134
  • 7
  • [ 6832-16-2 ]
  • [ 868-85-9 ]
  • [ 5927-18-4 ]
Reference: [1] Phosphorus, Sulfur and Silicon and the Related Elements, 1992, vol. 73, # 1-4, p. 153 - 160
  • 8
  • [ 96-32-2 ]
  • [ 121-45-9 ]
  • [ 5927-18-4 ]
Reference: [1] Liebigs Annalen der Chemie, 1985, # 2, p. 226 - 238
[2] Canadian Journal of Chemistry, 1968, vol. 46, p. 2225 - 2232
  • 9
  • [ 96-34-4 ]
  • [ 121-45-9 ]
  • [ 5927-18-4 ]
Reference: [1] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1996, vol. 35, # 4, p. 312 - 317
[2] Chemische Berichte, 1976, vol. 109, p. 2039 - 2063
[3] Tetrahedron Letters, 1999, vol. 40, # 8, p. 1455 - 1458
  • 10
  • [ 67-56-1 ]
  • [ 16139-79-0 ]
  • [ 311-46-6 ]
  • [ 5927-18-4 ]
  • [ 625396-69-2 ]
  • [ 625396-71-6 ]
Reference: [1] Chemical and Pharmaceutical Bulletin, 2005, vol. 53, # 1, p. 131 - 134
  • 11
  • [ 67-56-1 ]
  • [ 42451-44-5 ]
  • [ 5927-18-4 ]
Reference: [1] J. Gen. Chem. USSR (Engl. Transl.), 1976, vol. 46, p. 529 - 534[2] Zhurnal Obshchei Khimii, 1976, vol. 46, # 3, p. 534 - 540
  • 12
  • [ 67-56-1 ]
  • [ 4408-78-0 ]
  • [ 5927-18-4 ]
Reference: [1] J. Gen. Chem. USSR (Engl. Transl.), 1971, vol. 41, p. 1432 - 1439[2] Zhurnal Obshchei Khimii, 1971, vol. 41, p. 1426 - 1434
  • 13
  • [ 30361-28-5 ]
  • [ 5927-18-4 ]
  • [ 51544-64-0 ]
Reference: [1] Tetrahedron, 2005, vol. 61, # 15, p. 3651 - 3657
  • 14
  • [ 5927-18-4 ]
  • [ 33819-10-2 ]
  • [ 51544-64-0 ]
  • [ 77761-48-9 ]
Reference: [1] Tetrahedron, 2005, vol. 61, # 15, p. 3651 - 3657
  • 15
  • [ 5927-18-4 ]
  • [ 62924-31-6 ]
  • [ 69877-39-0 ]
  • [ 69877-38-9 ]
Reference: [1] Journal of Medicinal Chemistry, 1979, vol. 22, # 9, p. 1059 - 1067
  • 16
  • [ 5927-18-4 ]
  • [ 1122-91-4 ]
  • [ 75567-84-9 ]
Reference: [1] Chemistry Letters, 1998, # 3, p. 203 - 204
  • 17
  • [ 5927-18-4 ]
  • [ 865-47-4 ]
  • [ 62327-21-3 ]
Reference: [1] Patent: WO2009/81195, 2009, A1, . Location in patent: Page/Page column 29; 161-162
  • 18
  • [ 5927-18-4 ]
  • [ 1095142-51-0 ]
  • [ 1095142-53-2 ]
  • [ 1095142-55-4 ]
  • [ 50650-59-4 ]
Reference: [1] Patent: US2009/5569, 2009, A1, . Location in patent: Page/Page column 7
  • 19
  • [ 67-56-1 ]
  • [ 354-32-5 ]
  • [ 5927-18-4 ]
  • [ 109-92-2 ]
  • [ 50650-59-4 ]
Reference: [1] Patent: US2009/5569, 2009, A1, . Location in patent: Page/Page column 6-7
Same Skeleton Products
Historical Records

Pharmaceutical Intermediates of
[ 5927-18-4 ]

Belinostat Related Intermediates

Chemical Structure| 99-61-6

[ 99-61-6 ]

3-Nitrobenzaldehyde